Buy Albendazole

Albendazole

Albendazole: Generic Medication Overview

Albendazole is an antiparasitic (anthelmintic) medication used to treat a range of worm infections. It is available in a 400 mg oral pill form and is classified as a prescription-only product in Hong Kong. The drug works by interfering with the parasite’s ability to absorb glucose, leading to its death.

How Albendazole Works in the Body

Albendazole belongs to the benzimidazole class of antiparasitics. After oral ingestion, it is rapidly absorbed from the gastrointestinal tract; however, its bioavailability is modest because of extensive first-pass metabolism. The drug is converted in the liver to its active metabolite, albendazole sulfoxide, which circulates systemically and reaches most tissues, including the brain and skeletal muscle.

The active metabolite binds to β-tubulin in the parasite, preventing polymerisation of microtubules. This disrupts the parasite’s cytoplasmic structure, inhibits glucose uptake, and depletes its energy stores, ultimately causing immobilisation and death of the worm. Because human cells have a different β-tubulin isoform, the drug’s toxicity to human tissues is relatively low at therapeutic doses.

Onset of action is usually within a few days, with the greatest parasiticidal effect occurring after several consecutive doses, depending on the infection being treated.

Conditions Treated by Albendazole

Albendazole is approved in Hong Kong for the following indications, consistent with international regulatory guidance:

• Neurocysticercosis - infection of the central nervous system by the larval form of Taenia solium (pork tapeworm).
• Hydatid disease (Echinococcosis) - caused by Echinococcus granulosus or E. multilocularis; albendazole is used pre-operatively, post-operatively, or as a sole therapy when surgery is not feasible.
• Intestinal helminth infections - including Ascaris lumbricoides (roundworm), Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), and Strongyloides stercoralis (threadworm) when a single 400 mg dose is sufficient.
• Tissue-dwelling nematodes - such as Hookworm (Ancylostoma duodenale, Necator americanus), Trichinella spiralis (trichinosis), and Filariasis caused by Wuchereria bancrofti or Loa loa.

These uses are based on clinical trials, WHO recommendations, and the product label approved by the Hong Kong Department of Health.

Patient Suitability and Contraindications

Who should use Albendazole?

• Patients with confirmed or strongly suspected infections listed above.
• Individuals who are not pregnant (see contraindications).
• Adults and children ≥2 years of age; dosing for younger children is generally weight-based and must be prescribed by a qualified clinician.

Absolute Contraindications

• Known hypersensitivity to albendazole, any benzimidazole, or any of the tablet excipients.
• Pregnancy (especially first trimester) - albendazole is classified as Category D in many jurisdictions due to teratogenic risk.

Relative Contraindications

• Severe hepatic impairment: the drug is metabolised in the liver, and accumulation may increase toxicity.
• Pre-existing bone marrow suppression or severe leukopenia.

Special Populations

• Pregnancy & Lactation: Albendazole should be avoided unless the potential benefit outweighs the risk. It is excreted in breast milk; nursing mothers should discuss alternatives with their healthcare provider.
• Elderly: Dose adjustment may be required for those with reduced liver or kidney function.
• Renal Impairment: No specific dosage change is required for mild to moderate renal disease, but severe renal failure warrants careful monitoring.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal discomfort (nausea, abdominal pain, diarrhoea) - often mild and transient.
• Transient elevation of liver enzymes (ALT, AST) - usually resolves after therapy completion.
• Headache and dizziness - reported in up to 5 % of patients.

Serious Adverse Events

• Hepatotoxicity: Significant hepatic enzyme rise or clinical hepatitis; requires immediate medical assessment.
• Bone marrow suppression: Rare cases of leukopenia, pancytopenia, or aplastic anaemia have been documented.
• Allergic reactions: Rash, urticaria, or angioedema may occur; discontinue the drug if severe.

Drug Interactions

• CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin) can lower albendazole plasma concentrations, reducing efficacy.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase albendazole sulfoxide levels, potentially raising the risk of toxicity.
• Concurrent use with warfarin may enhance anticoagulant effect; frequent INR monitoring is advised.

Food and Lifestyle Interactions

• Albendazole tablets should be taken with a fatty meal to improve absorption; a high-fat snack (e.g., milk, yogurt, cheese) is recommended.
• Alcohol intake should be limited, as both alcohol and albendazole are metabolised by the liver, possibly increasing hepatic strain.
• No known impairment of driving or operating machinery, but patients experiencing dizziness should exercise caution.

How to Take Albendazole

• Standard dosing: For most intestinal helminths, a single 400 mg tablet taken with food is sufficient.
• Neurocysticercosis & Hydatid disease: Typically 400 mg orally twice daily for 28 days, with possible cycles and a break period as directed by the treating physician.
• Strongyloidiasis & Filariasis: 400 mg daily for 7 days, or as part of a longer course depending on disease severity.

Administration Tips

• Swallow the tablet whole; do not crush or chew.
• Take the dose with a fatty meal to enhance absorption.
• If a dose is missed, take it as soon as remembered on the same day; do not double the next dose.

Overdose

• Symptoms may include nausea, vomiting, abdominal pain, and elevated liver enzymes. Seek emergency medical care; supportive treatment is the mainstay. No specific antidote is available.

Discontinuation

• Abrupt cessation is acceptable for short courses. For prolonged therapy (e.g., neurocysticercosis), follow the prescriber’s tapering plan to reduce the risk of recrudescence.

Monitoring and Follow-Up

• Liver function tests (ALT, AST, bilirubin) before treatment, mid-course (if therapy exceeds 14 days), and after completion for hepatic-risk indications.
• Complete blood count for patients on extended regimens or with pre-existing marrow concerns.
• Clinical assessment of symptom resolution; imaging (e.g., MRI or CT) may be required for neurocysticercosis after therapy.

Storage and Handling

• Store tablets at 20-25 °C (68-77 °F), protected from light and moisture.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication beyond the expiration date printed on the packaging.

Medication-Specific Glossary

Albendazole sulfoxide

The active metabolite formed in the liver that exerts the antiparasitic effect throughout the body.

Bioavailability

The proportion of an administered dose that reaches systemic circulation in an active form.

Cytochrome P450 (CYP3A4)

A liver enzyme that metabolises many drugs, including albendazole; its activity influences drug-drug interaction risk.

Neurocysticercosis

A central nervous system infection caused by the larval stage of the pork tapeworm Taenia solium.

Therapeutic window

The dosage range that produces the desired therapeutic effect without causing unacceptable toxicity.

Medical Disclaimer

This article provides educational information about albendazole and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.